MULTRYS
Peaktrace elements injection 4
NDAINTRAVENOUSSOLUTION
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
MULTRYS (trace elements injection 4) is polymerases, rna polymerases, alcohol dehydrogenase, and alkaline phosphatases. Approved for copper, manganese, selenium for parenteral nutrition and 3 more indications. First approved in 2020.
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MULTRYS is a trace elements injection containing zinc, copper, manganese, and selenium for patients requiring parenteral nutrition when enteral nutrition is not possible or is insufficient. The drug works by providing essential cofactors for critical metalloenzymes involved in protein synthesis, oxidative stress defense, and cellular metabolism. It is indicated for supplementation in patients dependent on intravenous nutrition support.
Peak15.1 years to LOE
Product is in peak commercial phase with stable market position; commercial team size likely stable with maintenance-focused support.
Mechanism of Action
polymerases, RNA polymerases, alcohol dehydrogenase, and alkaline phosphatases. Zinc is a coordinator of protein structural folding that interacts with a variety of proteins, lipids, and nucleic acids. In addition, zinc is a catalyst of essential biochemical reactions, including activation of…
Indications (6)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.